Crossmark

Evaluation of the efficacy and safety of favipiravir and interferon compared to lopinavir/ritonavir and interferon in moderately ill patients with COVID-19: a structured summary of a study protocol for a randomized controlled trial

Crossref DOI link: https://doi.org/10.1186/s13063-020-04747-8

Published Online: 2020-10-27

Published Print: 2020-12

Update policy: https://doi.org/10.1007/springer_crossmark_policy

Authors

Hassaniazad, Mehdi

Bazram, Ali

Hassanipour, Soheil

Fathalipour, Mohammad https://orcid.org/0000-0002-4568-7024
Funding

Funding for this research was provided by:

Hormozgan University of Medical Sciences (990233)
License Information

Text and Data Mining valid from 2020-10-27

Version of Record valid from 2020-10-27
More Information

Article History

Received: 10 September 2020

Accepted: 16 September 2020

First Online: 27 October 2020

Ethics approval and consent to participate

: The RCT protocol was approved by the Ethics Committee of Hormozgan University of Medical Sciences (Ethics Committee reference number: ) on 21 July 2020. The investigators declare the trial has received ethical approval from the appropriate ethical committee, as described above. All participants freely signed informed consent before randomization.

: Not applicable.

: The authors declare that they have no competing interests.

Document is current

Any future updates will be listed below